Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Gross margin
Vertex Pharmaceuticals Incorporated's gross margin over the twelve months to 30 June 2026 was 86.0%, down 0.2 percentage points from fiscal 2025 (86.2%). Over the past ten years it has ranged from 86.1% (fiscal 2024) to 89.0% (fiscal 2017); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 86.2% | 0.13 |
| FY2024 | 86.1% | (1.10) |
| FY2023 | 87.2% | (0.69) |
| FY2022 | 87.9% | (0.16) |
| FY2021 | 88.1% | (0.08) |
| FY2020 | 88.1% | 1.30 |
| FY2019 | 86.8% | 0.28 |
| FY2018 | 86.6% | (2.39) |
| FY2017 | 89.0% | 1.31 |
| FY2016 | 87.6% | (0.30) |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 85.3% | (1.52) |
| Mar 2026 | 86.9% | 1.46 |
| Dec 2025 | 85.4% | (1.13) |
| Sep 2025 | 86.5% | 0.27 |
| 42 more quarters | Free account |
Against its own ten years
Low 86.1%
High 89.0%
Ten-year median
87.6%
Current reading's percentile
18
Gross margin against peers
| Company | Gross margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 100.0% |
| ARGX argenex SE compare | 90.2% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 88.9% |
| VRTX Vertex Pharmaceuticals Incorporated | 86.0% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 84.9% |
| INSM Insmed, Inc. compare | 83.5% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 79.7% |
| RVMD Revolution Medicines, Inc. compare | 35.1% |
| MRNA Moderna, Inc. compare | 23.4% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement